SCHADE CHRISTIAN S 4

4 · Aprea Therapeutics, Inc. · Filed Mar 14, 2022

Form 4

Period: 2022-03-10

DirectorPresident & CEO

Transactions

Award
Stock Option (right to Buy)
2022-03-10+427,700→ 427,700 total
Exercise: $1.82Exp: 2032-03-10→ Common Stock (427,700 underlying)
Award
Common Stock
2022-03-10+100,100→ 255,116 total

Holdings

Footnotes (3)

[F1]These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 33,366 shares on March 10, 2023, (ii) 33,367 shares on March 10, 2024 and (iii) 33,367 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
[F2]Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
[F3]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

Documents

1 file